Is Reflex Germline BRCA1/2 Testing Necessary in Women Diagnosed with Non-Mucinous High-Grade Epithelial Ovarian Cancer Aged 80 Years or Older?
暂无分享,去创建一个
G. Jayson | F. Lalloo | G. Burghel | E. Crosbie | A. Clamp | D. Evans | R. Edmondson | C. Mitchell | J. Hasan | E. Woodward | H. Schlecht | M. Bulman | N. Flaum | Philip Smith | Z. Salih | R. Morgan
[1] Yoonjung Kim,et al. Cost-Effectiveness Analysis of Germline and Somatic BRCA Testing in Patients With Advanced Ovarian Cancer , 2022, Annals of laboratory medicine.
[2] A. Oza,et al. Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects , 2022, Cancer research communications.
[3] J. Ledermann,et al. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] A. Oza,et al. Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma. , 2022, Gynecologic oncology.
[5] B. Monk,et al. A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45) , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] G. Jayson,et al. BRCA1/2 in non-mucinous epithelial ovarian cancer: tumour with or without germline testing? , 2022, British Journal of Cancer.
[7] A. Tinker,et al. Germline Testing and Somatic Tumor Testing for BRCA1/2 Pathogenic Variants in Ovarian Cancer: What Is the Optimal Sequence of Testing? , 2021, JCO precision oncology.
[8] A. Mullard,et al. The detection of germline and somatic BRCA1/2 genetic variants through parallel testing of patients with high‐grade serous ovarian cancer: a national retrospective audit , 2021, BJOG : an international journal of obstetrics and gynaecology.
[9] Vera M Witjes,et al. Probability of detecting germline BRCA1/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis. , 2021, Gynecologic oncology.
[10] A. Tinker,et al. Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer. , 2021, Gynecologic oncology.
[11] D. Berton,et al. Homologous recombination repair mutation gene panels (excluding BRCA) are not predictive of maintenance olaparib plus bevacizumab efficacy in the first-line PAOLA-1/ENGOT-ov25 trial , 2021, Gynecologic Oncology.
[12] A. Tinker,et al. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2) , 2021, Nature Communications.
[13] B. Karlan,et al. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.
[14] S. Ellard,et al. Combining evidence for and against pathogenicity for variants in cancer susceptibility genes: CanVIG-UK consensus recommendations , 2020, Journal of Medical Genetics.
[15] G. Jayson,et al. Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England , 2020, European Journal of Human Genetics.
[16] I. Campbell,et al. Exome sequencing of familial high-grade serous ovarian carcinoma reveals heterogeneity for rare candidate susceptibility genes , 2020, Nature Communications.
[17] N. Rahman,et al. Oncologist-led BRCA ‘mainstreaming’ in the ovarian cancer clinic: A study of 255 patients and its impact on their management , 2020, Scientific Reports.
[18] F. Marmé,et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. , 2019, The New England journal of medicine.
[19] M. Morgan,et al. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. , 2019, The New England journal of medicine.
[20] B. Monk,et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. , 2019, The New England journal of medicine.
[21] A. Tutt,et al. A decade of clinical development of PARP inhibitors in perspective , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] B. Taylor,et al. Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] A. Reuss,et al. Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883) , 2019, Journal of Medical Genetics.
[24] Angela Mariotto,et al. Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] G. Jayson,et al. Prevalence of germline pathogenic BRCA1/2 variants in sequential epithelial ovarian cancer cases , 2019, Journal of Medical Genetics.
[26] R. Glasspool,et al. Routine germline BRCA1 and BRCA2 testing in patients with ovarian carcinoma: analysis of the Scottish real‐life experience , 2018, BJOG : an international journal of obstetrics and gynaecology.
[27] C. Turnbull,et al. Consensus for genes to be included on cancer panel tests offered by UK genetics services: guidelines of the UK Cancer Genetics Group , 2018, Journal of Medical Genetics.
[28] J. Ledermann,et al. Mainstreamed genetic testing for women with ovarian cancer: first-year experience , 2018, Journal of Medical Genetics.
[29] Rochelle L. Garcia,et al. Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma. , 2017, Gynecologic oncology.
[30] B. Gilks,et al. Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes , 2015, British Journal of Cancer.
[31] T. Walsh,et al. Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study , 2017, Clinical Cancer Research.
[32] F. Couch,et al. Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls. , 2017, Gynecologic oncology.
[33] James X. Sun,et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.
[34] Ignace Vergote,et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. , 2016, The New England journal of medicine.
[35] Suzanne Miller,et al. New paradigms for BRCA1/BRCA2 testing in women with ovarian cancer: results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study , 2016, Journal of Medical Genetics.
[36] S. Seal,et al. Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients , 2016, Scientific Reports.
[37] Z. Szallasi,et al. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer , 2016, Clinical Cancer Research.
[38] Lara E Sucheston-Campbell,et al. Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. , 2015, Journal of the National Cancer Institute.
[39] Lara E Sucheston-Campbell,et al. Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] T. Chan,et al. The importance of analysis of long-range rearrangement of BRCA1 and BRCA2 in genetic diagnosis of familial breast cancer. , 2015, Cancer genetics.
[41] Shuwen Huang,et al. A reliable method for the detection of BRCA1 and BRCA2 mutations in fixed tumour tissue utilising multiplex PCR-based targeted next generation sequencing , 2015, BMC Clinical Pathology.
[42] Wei-Ting Hwang,et al. Effects of BRCA1- and BRCA2-Related Mutations on Ovarian and Breast Cancer Survival: A Meta-analysis , 2014, Clinical Cancer Research.
[43] D. Matei,et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. , 2014, The Lancet. Oncology.
[44] Jaime Prat,et al. Staging classification for cancer of the ovary, fallopian tube, and peritoneum , 2014, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[45] Figo Guidelines. Staging classification for cancer of the ovary, fallopian tube, and peritoneum☆ , 2013 .
[46] A. Vincent-Salomon,et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. , 2012, Cancer research.
[47] G. Mills,et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer , 2012, British Journal of Cancer.
[48] J. George,et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] Z. Szallasi,et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. , 2012, Cancer discovery.
[50] A. Gylfason,et al. Mutations in BRIP1 confer high risk of ovarian cancer , 2011, Nature Genetics.
[51] H. Mackay,et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. , 2011, The Lancet. Oncology.
[52] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[53] A. Falini,et al. Tumours , 2008, Neurological Sciences.
[54] R. Eeles,et al. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] D. Easton,et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancer , 2004, British Journal of Cancer.
[56] N. Rahman,et al. A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO , 2004, Journal of Medical Genetics.
[57] Samantha Sharpe,et al. Cancer Research UK , 2002, Nature Cell Biology.
[58] D. Berry,et al. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. , 1998, American journal of human genetics.